The RNA-Based Vaccine Market is segmented by route of administration into intramuscular, intravenous, and subcutaneous delivery. Intramuscular administration remains the preferred approach because of its established use in vaccination and its ability to generate effective immune responses.

Researchers are nevertheless exploring alternative delivery methods that could improve vaccine accessibility, stability, and patient convenience. Advances in RNA delivery systems and formulations are expected to support the development of new administration approaches.

Improving RNA stability and delivery efficiency is particularly important for expanding applications beyond conventional vaccination programs.